Hansen Medical, Inc. (NASDAQ:HNSN) To Showcase Innovations At SIR Annual Scientific Meeting


Dallas, Texas 03/20/2014 (FINANCIALSTRENDS) –  Hansen Medical, Inc. (NASDAQ:HNSN), a provider of intravascular robotics, said the company will present its Magellan Robotic System and its new 6Fr Robotic Catheter at the Society of Interventional Radiology’s (SIR) Annual Scientific Meeting, to be held from March 23-27 at the San Diego Convention Center.

At Booth 800, the company is expected to showcase product demonstrations and new innovations, and also exhibit the Magellan Robotic System.

Hansen will also sponsor a symposium, where the company will “discuss the new Magellan 6Fr Robotic Catheter and its potential to expand the role of Intravascular Robotics to include peripheral vascular procedures in smaller vessels.”

Chris Lowe, Interim CEO of Hansen Medical, said, “With the recent FDA 510(k) clearance for our Magellan 6Fr Catheter, we will be expanding the clinical applications for Intravascular Robotics to include procedures in smaller diameter vessels, many of which are performed by Interventional Radiologists. We are excited for the opportunity to showcase our Magellan System and the new catheter in this forum.”

Recently, Hansen Medical, Inc. (NASDAQ:HNSN) saw some insider buying activity happening on March 11, 2014. In a filing with the U.S. SEC, the company reported that Hansen Medical director Michael Eagle bought 10,000 shares of the company’s stock on the open market.

The shares were bought at an average price of $2.29 per share, and the total value of the transaction was $22,900.00. Following the completion of the shares acquisition, the director Michael Eagle now directly owns 16,250 shares of Hansen Medical, Inc. (NASDAQ:HNSN)’s stock, valued at about $37,213.

The company last posted its quarterly earnings on February 20th. Hansen Medical reported $0.12 loss per share, beating the Thomson Reuters consensus estimate of $0.14 loss per share. The revenue for the quarter was $5.60 million versus consensus estimates’ of $5.90 million. Hansen Medical is expected to post $0.40 loss per share for the current fiscal year by the consensus.